STOCK TITAN

Vanguard affiliate reports zero holdings in Edwards Lifesciences (NYSE: EW)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Edwards Lifesciences Corp ownership update: The Vanguard Group filed an amendment reporting 0 shares beneficially owned and 0% of common stock as of the amendment. The filing explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026
Edwards Lifesciences Corp

NYSE:EW

View EW Stock Overview

EW Rankings

EW Latest News

EW Latest SEC Filings

EW Stock Data

47.68B
577.57M
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
IRVINE